2138 related articles for article (PubMed ID: 22160255)
21. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
22. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
23. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
24. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
25. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
27. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
28. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
29. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
30. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
Ueda K; Yokoyama M; Asai H; Koudaira M; Yamada S; Katsube A; Mishima Y; Sakajiri S; Takeuchi K; Saotome T; Terui Y; Takahashi S; Hatake K
Gan To Kagaku Ryoho; 2010 May; 37(5):853-7. PubMed ID: 20495315
[TBL] [Abstract][Full Text] [Related]
32. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
34. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
38. Survival of patients with transformed lymphoma in the rituximab era.
Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
[TBL] [Abstract][Full Text] [Related]
39. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
40. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.
Castillo JJ; Sinclair N; Beltrán BE; Song MK; Ilic I; Leppa S; Nurmi H; Seki R; Uccella S; Li JM; Treaba DO; Stachurski D; Butera JN
Leuk Res; 2013 Apr; 37(4):386-91. PubMed ID: 23352640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
